Aravive to Participate in H.C. Wainwright Global Investment Conference
May 17 2022 - 7:00AM
Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology
company developing targeted therapeutics to treat metastatic
disease today announced that Gail McIntyre, Ph.D, DABT, Chief
Executive Officer will present at the H.C. Wainwright Annual Global
Investment Conference being held at the Fontainebleau Miami Beach
Hotel May 23-26, 2022.
What: H.C. Wainwright Annual
Global Investment ConferenceWhere: Fontainebleau
Miami Beach HotelWhen: May 25, 2022, 10:00 am ET –
10:30 am ETLive and archived webcast:
https://ir.aravive.com/events-and-presentations
About AraviveAravive, Inc. is a
late clinical-stage oncology company developing targeted
therapeutics to treat metastatic disease. Our lead product
candidate, batiraxcept (formerly AVB-500), is an ultra-high
affinity decoy protein that binds to GAS6, the sole ligand that
activates AXL, thereby inhibiting metastasis and tumor growth, and
restoring sensitivity to anti-cancer agents. Batiraxcept has been
granted Fast Track Designation by the U.S. FDA and Orphan Drug
Designation by the European Commission in platinum-resistant
recurrent ovarian cancer. Batiraxcept is in an active
registrational Phase 3 trial in platinum resistant ovarian cancer
(NCT04729608), a Phase 1b/2 trial in clear cell renal cell
carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic
adenocarcinoma (NCT04983407). The Company is based in Houston,
Texas and received a Product Development Award from the Cancer
Prevention & Research Institute of Texas (CPRIT) in 2016.
Additional information at www.aravive.com.
Contact:Marek Ciszewski, J.D.Vice President,
Investor RelationsMarek@Aravive.com(562) 373-5787
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Apr 2023 to Apr 2024